The TP53 mutation rate at diagnosis was twice as high compared to the West (20.5% vs. 7 ~ 13% respectively), and the higher mutation rate might partly explain the poor outcomes of CLL patients in Taiwan. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.